3DSkema is launching a new marketplace to enable the rapid sharing and development of microfluidic designs for the research and industry communities.
More than 250 companies have been started by UW students and faculty or with UW technology
Accelerator Corporation (formerly XORI) is a vehicle for capital-efficient investment in and management of emerging biotechnology opportunities. Formed by a syndicate of top-tier venture capital investors and supported by a consortium of world-class research institutions, Accelerator identifies, evaluates, finances, and manages the commercialization of technologies and assets sourced from a broad range of proprietary sources.
Answerdash has developed contextual Q&A technology that provides website and web application users with instant context-sensitive answers right when and where they need them. As users ask new questions over time, an “answer layer” builds up over a site or application, enabling future visitors to find answers easily without having to ask again.
Aortica Corporation has developed a patient-specific solution for individuals with abdominal aortic aneurysm disease that will allow physicians to treat patients with endografts precisely matched to their anatomy.
Applied Dexterity’s goal is to advance the field of robotically assisted surgery by creating a research surgical robot that fosters collaboration. Researchers can program and modify the RAVENTM system but it serves as a standard platform so that they can share their software and improvements. RAVEN is designed to be an extensible, robust, and programmable research tool to allow researchers in engineering, surgery, and computer science to experiment, innovate, and collaborate.
Aqueduct Neurosciences was founded with the mission to improve the treatment of neurological disorders related to the production and regulation of cerebral spinal fluid (CSF).
Artemesia BioMedical is the first biotechnology company to pioneer the development and commercialization of novel redesigned and repurposed artemisinin anti-malarial compounds for the treatment of cancer, inflammation and infectious diseases.
Arzeda has the world-leading computational enzyme design technology and is changing the way people think about biocatalysis. Arzeda's team includes the inventors of the platform and brings more than 20 years of combined experience in the field of computational and experimental protein engineering.
AttoDx is a biotechnology company developing applications for its proprietary Molecular Viability Testing (MVT). They partner with other companies and institutions to integrate this technology into various detection and diagnostic devices and instruments.
BEAT BioTherapeutics is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. BEATBio holds worldwide rights to this technology and its UW founders are recognized experts in cardiovascular biology, muscle physiology and bioengineering.
BluHaptics gives operators the ability to intuitively control complex robotic systems. Their visual interface, in combination with their patent-pending technology for force feedback, gives the operator unprecedented control of critical remote operations. This means less focus on robotics and more focus on getting the job done.
C-SATS (Crowd-Sourced Assessment of Technical Skills) offers a performance management system for evaluating and improving technique in healthcare professionals rapidly, accurately and cost effectively.
Cardiac Insight is developing proprietary algorithms, software and hardware designed for the monitoring of patients with cardiac arrhythmias.
CisThera mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases. CisThera is taking a novel approach to identify drugs with greater efficacy that broadly inhibit validated contributors to disease pathogenesis.
Compliment Corporation is a biotechnology company developing therapeutics in oncology. Its mission is to improve cancer treatment by increasing the effectiveness of cancer drugs and by reducing the toxicities associated with standard chemotherapy treatment.
Corensic helped fuel the multicore revolution with Jinx-the world's first debugging tool for multi-threaded software applications. It was acquired by F5 Networks in 2012.
Cyrus Biotechnology is creating an easy-to-use version of the Rosetta software package developed in the lab of UW Professor of Biochemistry David Baker so scientists can sort through large data sets, design proteins and bring drugs to market faster.
Dato (formerly GraphLab) is a graph-based, high performance, distributed computation framework written in C++. While Dato was originally developed for machine learning tasks, it has found success in a broad range of data-mining tasks, out-performing other abstractions by orders of magnitude.
Deurion has developed a unique method to perform diagnostics and mass spectrometry, an analytical technique that produces spectra of the masses of atoms or molecules constituting a sample of material.
- 1 of 5